Animal Health

Sensitive screening for infectious bovine rhinotracheitis

The IDEXX IBR gB X3 Ab Test is an enzyme immunoassay for the detection of glycoprotein-B-specific antibodies to bovine herpesvirus-1 (BHV-1) in bovine serum, plasma and milk samples using IBR gB-specific monoclonal antibodies.

BHV-1 is the causative agent of infectious bovine rhinotracheitis (IBR), a highly contagious, infectious disease. Typical clinical signs associated with infection include respiratory disease, but the virus can also cause conjunctivitis, vulvovaginitis, abortions, encephalitis and balanoposthitis. The transition from primary manifestations of infection to a latent stage of persistency is often the source of spread after virus reactivation. Confirmation of exposure to BHV-1 is facilitated by a measurement of antibody.

  • Highly sensitive blocking ELISA format
  • Rapid test method—short (less than 4 hours) and overnight protocols
  • Five-plate (strips) and 30-plate (solid) formats
  • Ready-to-use reagents
  • Easy to automate
  • Compatible with xChekPlus* software

 

Specificity: European negative population

Distribution of European Negative Panel Sera (n=977) and Plasma (n=338)—Day Incubation

European Negative Population

Serum samples from Switzerland (n=594)—5 populations
Serum samples from Germany (n=316)—2 populations
Serum samples from Spain (n=67)—1 population
Plasma samples from Switzerland (n=98)—3 populations
Plasma samples from Austria (n=240)—1 population
Total N=1,315

Interpretation of results: Values <45% are negative; values between 45–55% are suspect; values >55% are positive.

Conclusion: Specificity reached 99.8% for both the IDEXX IBRgB X3 Ab Test and IDEXX IBRgB X2 Ab Test in this large and varied set of negative samples.

 

Sensitivity: Temporal Sera

BHV-1—Exposed Temporal Sera

Temporal Sera

To demonstrate equivalence of test performances between the current IDEXX IBR gB X2 Ab Test (referred to as the SOP) and the new IDEXX IBR gB X3 Ab Test, serum samples were collected from a gE vaccinated animal in Germany that was determined to be positive. Samples were collected Day 3–Day 60 postvaccination and then tested on three lots of the IDEXX IBR gB X3 Ab Test and three lots of the IDEXX IBRgB X2 Ab Test (SOP).

Interpretation of results: Values <45% are negative; values between 45–55% are suspect; values >55% are positive.

Conclusion: The animal evidenced a positive status 12 days postvaccination when tested on all lots of the IDEXX IBR gB X3 Ab Test and the IDEXX IBRgB X2 Ab Test. The kinetic curves appear similar, demonstrating homogeneity between lots.

 

Sensitivity

Testing of German, French and European Reference Samples—Day Incubation

Sensitivity

To demonstrate equivalence of test performances between the current IDEXX IBR gB X2 Ab Test (referred to as the SOP) and the new IDEXX IBR gB X3 Ab Test, test results from German, French and European reference samples were compared.

Interpretation of results: Values <45% are negative; values between 45–55% are suspect; values >55% are positive.

Conclusion: Performance of the IDEXX IBRgB X3 Ab Test was equivalent to the IDEXX IBRgB X2 Ab Test. Both tests demonstrated 100% agreement with expected results, including samples known to have BHV-1 antibody titers that were detected as positive samples.

Sigma Aldrich Idexx Laboratories Romerlabs LP ITALIANA Carl Zeiss
 Thermo Scientific  Nunc Finnpipette QSP  Molecular Bio Products
LI-COR Honeywell MPW
Interscience
     Hygiena Logo